Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Accounts Payables (2019 - 2026)

Opus Genetics has reported Accounts Payables over the past 13 years, most recently at $4.4 million for Q1 2026.

  • Quarterly Accounts Payables rose 81.98% to $4.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Mar 2026, up 81.98% year-over-year, with the annual reading at $3.3 million for FY2025, 4.61% up from the prior year.
  • Accounts Payables was $4.4 million for Q1 2026 at Opus Genetics, up from $3.3 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $4.4 million in Q1 2026 and troughed at $634000.0 in Q2 2024.
  • The 5-year median for Accounts Payables is $2.1 million (2024), against an average of $2.1 million.
  • Year-over-year, Accounts Payables crashed 72.71% in 2024 and then skyrocketed 183.77% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $1.1 million in 2022, then skyrocketed by 101.4% to $2.2 million in 2023, then soared by 46.21% to $3.1 million in 2024, then rose by 4.61% to $3.3 million in 2025, then soared by 34.28% to $4.4 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Accounts Payables are $4.4 million (Q1 2026), $3.3 million (Q4 2025), and $2.4 million (Q3 2025).